+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Clear Cell Renal Cell Carcinoma (ccRCC) - Pipeline Insight, 2024 - Product Thumbnail Image

Clear Cell Renal Cell Carcinoma (ccRCC) - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Liver Disease Associated Pruritus - Pipeline Insight, 2024 - Product Thumbnail Image

Liver Disease Associated Pruritus - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Hepatic Cirrhosis - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatic Cirrhosis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Liver Fibrosis - Pipeline Insight, 2024 - Product Thumbnail Image

Liver Fibrosis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 85 Pages
  • Global
From
Oncocytoma - Pipeline Insight, 2024 - Product Thumbnail Image

Oncocytoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Renal Impairment - Pipeline Insight, 2024 - Product Thumbnail Image

Renal Impairment - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
VEMLIDY Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

VEMLIDY Market Size, Forecast, and Market Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
ASC22 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

ASC22 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
Chronic Liver Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Liver Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Renal cell carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Renal cell carcinoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Late-stage chronic kidney disease (CKD) - Pipeline Insight, 2024 - Product Thumbnail Image

Late-stage chronic kidney disease (CKD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Nephropathic Cystinosis - Pipeline Insight, 2024 - Product Thumbnail Image

Nephropathic Cystinosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Chronic Renal/Kidney Transplant Rejection - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Renal/Kidney Transplant Rejection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Cystinosis - Pipeline Insight, 2024 - Product Thumbnail Image

Cystinosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetic Kidney Disease (DKD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Distal Renal Tubular Acidosis (dRTA) - Pipeline Insight, 2024 - Product Thumbnail Image

Distal Renal Tubular Acidosis (dRTA) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Focal Segmental Glomerulosclerosis - Pipeline Insight, 2024 - Product Thumbnail Image

Focal Segmental Glomerulosclerosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Primary Hyperoxaluria - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Hyperoxaluria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more